



CLAIMS


1. An inhibitor for inhibiting macrophage activation, comprising a compound represented by the following general formula (1) or its pharmacologically acceptable salt as an active ingredient,




wherein R^1 represents a hydrogen atom or a C2 to C4 alkanoyl group and R^2 represents a group represented by the following formula (A), (B), (C), (D), (E), (F), or (G):




(A)




(B)




(C)




(D)



(E)





(F)




(G)

wherein R^3 represents a C1 to C4 alkyl group.

2. The inhibitor of claim 1, wherein the compound is the following formula (1a) or formula (1b):



3. The inhibitor of claim 1, wherein the compound is the following formula (2):



4. The inhibitor of any one of claims 1 to 3, which prevents, improves, or treats a disease resulting from macrophage activation.

5. The inhibitor of claim 4, wherein the disease is an infectious disease.

6. The inhibitor of claim 5, wherein the infectious disease results from infection with a bacterium.

7. The inhibitor of claim 6, wherein the bacterium is a Gram-negative bacterium.

8. The inhibitor of claim 5, wherein the infectious disease results from infection with a virus.

9. The inhibitor of claim 8, wherein the virus is influenza.


10. The inhibitor of claim 4, wherein the disease is a type IV allergic disease.

11. The inhibitor of any one of claims 1 to 3, which prevents, improves, or treats severity of an atopic disease associated with pathogenic infection.








12. The inhibitor of any one of claims 1 to 3, wherein the macrophage activation results from any one factor selected from the group consisting of lipopolysaccharide, IFN- γ , and IL-1 β .

13. A therapeutic agent for an infectious disease, comprising

a compound represented by the following general formula (1) or its pharmacologically acceptable salt as an active ingredient:





wherein R^1 represents a hydrogen atom or a C2 to C4 alkanoyl group and R^2 represents a group represented by the following formula (A), (B), (C), (D), (E), (F), or (G):




wherein R^3 represents a C1 to C4 alkyl group.

14. The therapeutic agent for an infectious disease of claim 13, wherein the compound is the following formula (1a) or formula (1b):




15. The therapeutic agent for an infectious disease of claim


13, wherein the compound is the following formula (2):




16. A therapeutic agent for a type IV allergic disease, comprising a compound represented by the following general formula (1) or its pharmacologically acceptable salt as an active ingredient:




wherein R^1 represents a hydrogen atom or a C2 to C4 alkanoyl group and R^2 represents a group represented by the following formula (A), (B), (C), (D), (E), (F), or (G):




(A)




(B)




(C)




(D)



(E)




(F)




(G)

wherein R^3 represents a C1 TO C4 alkyl group.


17. The therapeutic agent for a type IV allergic disease of claim 16, wherein the compound is the following formula (1a) or formula (1b):




18. The therapeutic agent for a type IV allergic disease of claim 16, wherein the compound is the following formula (2):



19. A therapeutic agent for improving severity of an atopic disease associated with pathogenic infection, comprising a compound represented by the following general formula (1) or its pharmacologically acceptable salt as an active ingredient:




wherein R^1 represents a hydrogen atom or a C2 to C4 alkanoyl group and R^2 represents a group represented by the following formula (A), (B), (C), (D), (E), (F), or (G):



wherein R^3 represents a C1 to C4 alkyl group.

20. The therapeutic agent of claim 19, wherein the compound is the following formula (1a) or formula (1b):



21. The therapeutic agent of claim 19, wherein the compound is the following formula (2):

